PRV 3279
Alternative Names: Anti-CD32B-anti-CD79B-bispecific-monoclonal-antibody; CD32BxCD79B; MGD 010; PRV-3279Latest Information Update: 06 May 2025
At a glance
- Originator MacroGenics
- Developer Provention Bio
- Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIA antagonists; Fc gamma receptor IIB antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- No development reported Autoimmune disorders
Most Recent Events
- 25 Apr 2025 Provention Bio terminates a phase II trial in Systemic lupus erythematosus in USA, Puerto Rico, China (IV) due to change in strategy (NCT05087628)
- 28 Sep 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (IV)
- 27 Apr 2023 Provention Bio has been acquired by Sanofi